Pinealon: Discovery and Research History

Introduction

Pinealon (Glu-Asp-Arg; EDR) did not emerge from a single discrete discovery event. Its development traces through several decades of Soviet and post-Soviet Russian biomedical research aimed at isolating pharmacologically active peptide sequences from mammalian organ tissues. The compound is a product of a systematic program initiated by Vladimir Kh. Khavinson and colleagues that evolved over decades into the field now described in published literature as peptide bioregulation. Understanding Pinealon requires understanding this broader research lineage — one of the most extensively published programs in short peptide pharmacology.

Discovery Period: Soviet Origins of Pineal Peptide Research

The intellectual foundation of Pinealon's development lies in Soviet-era biomedical research programs of the 1970s and early 1980s. Vladimir Kh. Khavinson and Vyacheslav G. Morozov, working at what would become the St. Petersburg Institute of Bioregulation and Gerontology, pursued work on low-molecular-weight peptide complexes extracted from bovine organ and tissue sources, including the pineal gland (epiphysis cerebri), thymus, cerebral cortex, and other organ systems [1].

The original research program operated under the auspices of the Soviet Ministry of Defence and was initially directed at identifying means to protect military personnel against environmental stressors including radiation. The methodology centered on aqueous or acetic-acid extraction of soluble peptides from fresh tissue, followed by fractionation and characterization of the resulting polypeptide complexes. From pineal tissue, this process yielded a preparation designated Epithalamin — a polypeptide complex containing multiple short peptide sequences [1].

This early period produced a substantial body of Soviet-era publications. Reviews of the program published in English-language journals describe it as generating over 700 publications spanning more than 40 years of research activity [1].

Early Research: From Complex Extracts to Defined Sequences

The transition from complex polypeptide preparations to defined short synthetic peptides represented a significant methodological advance within the Khavinson program. As sequencing and peptide synthesis techniques became more accessible during the 1990s, the Khavinson group and collaborators moved toward identifying the minimal active peptide sequences within their organ-derived preparations and synthesizing these as pure compounds.

For the pineal research lineage, this transition produced two key compounds: Epithalon (Ala-Glu-Asp-Gly; AEDG), a synthetic tetrapeptide that accumulated a substantial body of English-language publication, particularly in the context of melatonin regulation and pineal function in aged primates; and Pinealon (Glu-Asp-Arg; EDR), a synthetic tripeptide that became the focus of neuroprotection-oriented in vitro and rodent research in the 2000s and 2010s.

A study by Goncharova, Vengerin, Khavinson, and Lapin published in Experimental Gerontology in 2005 reported that pineal peptides — in this context examining Epitalon — were associated with altered hormonal parameters in aging rhesus macaques, including changes in melatonin secretion patterns [2]. While this study examined Epitalon rather than the EDR sequence, it illustrates the translational research context from which Pinealon's more detailed characterization emerged.

A broader review of the peptide bioregulation program published by Anisimov and Khavinson in Biogerontology in 2010 contextualized the scientific lineage, summarizing rodent studies reporting that long-term treatment with pineal peptide preparations was associated with increased mean lifespans in rodent populations [1]. This review establishes the scientific framework within which the EDR tripeptide was later characterized.

Research Milestones: Characterization of the EDR Sequence

The characterization of the EDR (Glu-Asp-Arg) tripeptide as a defined synthetic entity with measurable pharmacological properties in cell systems emerged primarily from work published from 2008 onward in English-accessible journals. Kozina's 2008 publication in Advances in Gerontology examined antihypoxic properties of short peptides including Pinealon, reporting that it demonstrated the most pronounced protective activity among the peptides examined in that experimental system [3].

The 2011 publication by Fedoreyeva, Kireev, Khavinson, and Vanyushin in Biochemistry (Moscow) provided detailed experimental characterization of nuclear penetration by the EDR sequence, demonstrating via fluorescence microscopy that labeled EDR peptide was detectable within the nuclei of HeLa cells and showing in vitro DNA-binding activity [4]. This study established the empirical foundation for the epigenetic gene-regulation hypothesis that subsequent publications from the Khavinson group would elaborate.

In the same year, the study by Khavinson, Ribakova, Kulebiakin, and colleagues published in Rejuvenation Research provided the first detailed description of Pinealon's in vitro effects on ROS accumulation, cell viability, and ERK signaling across multiple cell types [5]. This publication, appearing in a Western peer-reviewed journal, marked Pinealon's entry into the English-language literature as a characterized compound with specific in vitro properties.

Umnov, Lin'kova, and Khavinson published a review in Advances in Gerontology in 2013 situating Pinealon alongside polypeptide preparations (Cortexin, Cerebrolysin) and other short peptides (Semax, Kortagen) as part of a comparative characterization of neuroprotective agents examined in both cellular and clinical contexts [6]. This review contextualizes Pinealon's place within the broader Russian neuroprotective peptide research landscape.

Current Research Landscape

From 2014 onward, published research on Pinealon has focused on elaborating its gene-regulatory interactions through molecular docking methods and on extending the in vivo evidence base using genetic and pharmacological rodent models. The 2014 publication in the Bulletin of Experimental Biology and Medicine describing EDR-associated serotonin pathway effects [7], the 2020 Molecules paper detailing Alzheimer's-related gene promoter interactions [8], and the 2021 Pharmaceuticals study in 5xFAD mice [9] represent the most recent tier of published English-language research on the compound.

The compound has attracted attention in research communities beyond Russia, reflected in its appearance in English-language review articles and its availability through research compound suppliers in North America and Europe. The 2020 publication from Karantysh, Fomenko, and colleagues at an institution separate from the Khavinson laboratory [10] represents an expansion of the research base, with investigators applying Pinealon to diabetic rat models of cognitive disruption and NMDA receptor gene expression — a context distinct from the original neuroprotective framing.

Pinealon's regulatory status as a research compound reflects its current position in the scientific development cycle. The preclinical evidence base — spanning multiple in vitro systems, five or more distinct rodent models, and an extending molecular docking literature — provides the foundation from which translational research efforts can build. A fuller account of the compound's chemistry and classification is available in the Pinealon research overview. The Pinealon product page provides current batch verification data for researchers acquiring the compound.

References

1. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149. doi: 10.1007/s10522-009-9249-8. PMID: 19830585.

2. Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. 2005;40(1–2):51–57. doi: 10.1016/j.exger.2004.10.004. PMID: 15664732.

3. Kozina LS. Investigation of antihypoxic properties of short peptides. Advances in Gerontology. 2008;21(1):61–67. PMID: 18546825.

4. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210–1219. doi: 10.1134/S0006297911110022.

5. Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Research. 2011;14(5):535–541. doi: 10.1089/rej.2011.1172.

6. Umnov RS, Lin'kova NS, Khavinson VKh. Neuroprotective effects of peptides bioregulators in people of various age. Advances in Gerontology. 2013;26(4):671–678. PMID: 24738258.

7. Khavinson VKh, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO. Short peptides stimulate serotonin expression in cells of brain cortex. Bulletin of Experimental Biology and Medicine. 2014;157(1):77–80. doi: 10.1007/s10517-014-2496-y.

8. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020;26(1):159. doi: 10.3390/molecules26010159. PMID: 33396470.

9. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective effects of tripeptides — epigenetic regulators in mouse model of Alzheimer's disease. Pharmaceuticals (Basel). 2021;14(6):515. doi: 10.3390/ph14060515. PMID: 34071923.

10. Karantysh GV, Fomenko MP, Menzheritskii AM, Prokof'ev VN, Ryzhak GA, Butenko EV. Effect of pinealon on learning and expression of NMDA receptor subunit genes in the hippocampus of rats with experimental diabetes. Neurochemical Journal. 2020;14(3):314–320. doi: 10.1134/S181971242003006X.